Novartis AG (NVS) To Present New Data on Kesimpta at ECTRIMS 2025 in Barcelona

​Novartis AG (NYSE:NVS) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 24, ​Novartis AG (NYSE:NVS) announced that new data on Kesimpta for relapsing multiple sclerosis will be presented at ECTRIMS 2025 in Barcelona from September 24 to September 26.

This data comes from two studies. Firstly, the ARTIOS study evaluated patients who switched to Kesimpta after their disease worsened on oral therapies like fingolimod or fumarate. The results showed a major drop in disease activity with the annualized relapse rate falling to 0.06 over 96 weeks. Moreover, MRI scans showed near-complete suppression of lesions, with over 90% patients having no evidence of disease activity, called NEDA-3.

​Secondly, the ALITHIOS study looked at newly diagnosed, treatment-naive patients on first-line continuous Kesimpta for up to seven years. The results show that more than 90% achieved NEDA-3 in seven years. The long-term benefits included sustained low relapse rates, strong MRI lesion control, and a favorable safety profile with no new concerns.

Novartis AG (NYSE:NVS) is a Swiss multinational pharmaceutical company. It develops, manufactures, and markets branded and generic prescription drugs, biosimilars, and active pharmaceutical ingredients.

While we acknowledge the potential of NVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.